Table 2.

Univariate and multivariate analyses of factors for composite VTE during the follow-up period

Items	Category	n	Events, n (%)	Univariate			Multivariate
				HR	95% CI	p value	HR	95% CI	p value
Age, years	< 65	601	16 (2.7)	–	–	–
	≥ 65	280	15 (5.4)	2.07	0.999–4.267	0.0475
BMI, kg/m2	< 18.5	76	1 (1.3)	–	–	–
	18.5 to < 25	534	17 (3.2)	2.47	0.495–44.759	0.3834
	≥ 25	269	13 (4.8)	3.81	0.74–69.75	0.2008
Cancer occurrence	Primary	839	30 (3.6)	–	–	–
	Recurrence	42	1 (2.4)	0.66	0.036–3.192	0.6839
Cancer stage	I–II	668	15 (2.2)	–	–	–	–	–	–
	III–IV	213	16 (7.5)	3.54	1.71–7.349	0.0006	1.68	0.740–3.801	0.2131
Cancer type	Cervical	236	8 (3.4)	–		–
	Endomtrial	424	12 (2.8)	0.86	0.348–2.211	0.7356
	Ovary, Fallopian tube, Peritoneal	233	11 (4.7)	1.41	0.561–3.71	0.4667
Histology	Others	845	30 (3.6)	–	–	–	–	–	–
	Clear cell	36	1 (2.8)	0.78	0.043–3.791	0.8059	0.64	0.035–3.305	0.675
ECOG PS	0	797	25 (3.1)	–	–	–	–	–	–
	1–2	84	6 (7.1)	2.38	0.861–5.613	0.0656	1.52	0.526–3.805	0.3992
Surgery	No	152	11 (7.2)	–	–	–	–	–	–
	Yes	729	20 (2.7)	0.36	0.172–0.797	0.0085	0.53	0.242–1.211	0.1171
Chemotherapy	No	391	4 (1.0)	–	–	–	–	–	–
	Yes	490	27 (5.5)	5.64	2.183–19.21	0.0014	3.85	1.387–13.632	0.0176
Bevacizumab	No	847	28 (3.3)	–	–	–	–	–	–
	Yes	34	3 (8.8)	2.83	0.653–8.564	0.101	1.41	0.309–4.666	0.6066
VTE at baseline	No	830	26 (3.1)	–	–	–	–	–	–
	Yes	51	5 (9.8)	3.36	1.098–8.494	0.0177	2.24	0.689–6.148	0.1419

BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, VTE venous thromboembolism